Patrick G. Enright, Director at Jazz Pharmaceuticals plc (JAZZ), sold 19,260 shares at $169.69 ($3.2M) on 2018-09-06, disclosed to the SEC on 2018-09-07.
Open-market sale of $3.2M JAZZ by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $167.96 | 2,044 | $343K | 10.6% |
| 2 | $167.96 | 2,044 | $343K | 10.6% |
| 3 | $168.86 | 7,086 | $1.2M | 36.8% |
| 4 | $168.86 | 7,086 | $1.2M | 36.8% |
| 5 | $169.69 | 1,000 | $170K | 5.2% |
| Total | $168.71 avg | 19,260 |
| $3.2M |
| 100% |
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.5M | — | Filing → |
| VERA | BUY | 2025-06-25 | $10.6M | — | Filing → |
| BIOA | BUY | 2024-09-27 | $7.2M | — | Filing → |